LONDON–(BUSINESS WIRE)–BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, will announce its preliminary results for the year ended 31 December 2022 on Thursday, 16 March 2023.
Management will host an in-person briefing for analysts at 09:30 GMT on the day of the results at the offices of FTI Consulting (200 Aldersgate, Aldersgate Street, London EC1A 4HD). The event will also be accessible via webcast and a recording of the presentation will be made available on the Company’s website shortly afterwards.
To register your interest in attending either in person or virtually, please contact FTI Consulting at [email protected] or +44 (0) 20 3727 1000.
About BenevolentAI
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of this AI platform, its scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers the Company’s in-house drug pipeline and supports successful collaborations with AstraZeneca, as well as leading research and charitable institutions.
Contacts
Enquiries:
BenevolentAI
Investors:
Fleur Wood – VP Investor Relations
[email protected]
Media:
Rajin Kang – VP Communications
[email protected]
FTI Consulting:
Ben Atwell, Simon Conway, Victoria Foster Mitchell
+44 (0) 20 3727 1000
[email protected]